Oncomatryx, a biopharmaceutical company developing antibody-drug conjugates (ADCs), secured €25 million to advance clinical trials of OMTX705, a first-in-class ADC targeting Fibroblast Activation Protein (FAP). The funding round, supported by existing investors and a €10 million strategic investment from Centro para el Desarrollo Tecnológico y la Innovación (CDTI), will enable Phase Ib-II trials. This financial backing underscores the potential of OMTX705 to address unmet needs in metastatic solid tumors.
This investment is particularly significant as it fuels the clinical development of a novel approach to cancer treatment. Targeting the tumor microenvironment, specifically FAP-expressing cancer-associated fibroblasts (CAFs), represents a promising strategy for disrupting the tumor’s support system and enhancing therapeutic efficacy. Successful clinical trials could validate this approach, potentially opening doors for a new class of cancer therapies and significantly impacting patient outcomes.
The €25 million infusion enables Oncomatryx to conduct crucial Phase Ib-II studies for OMTX705, providing critical data on safety, efficacy, and optimal dosing. The substantial investment from CDTI further validates the scientific and commercial promise of Oncomatryx’s technology. Phase I clinical trial results are expected to be presented at major oncology conferences throughout 2025.
This funding positions Oncomatryx to significantly advance the development of its lead candidate and potentially reshape the landscape of cancer treatment. Positive clinical data could attract further investment and partnerships, accelerating the development and commercialization of this promising ADC and ultimately offering new hope for patients with metastatic solid tumors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
